Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, MD, Thomas S. Larsen, MD, Judit M. Jørgensen, MD PhD, Peter de Nully Brown, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-133359

Published: 2020

Journal Articles

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Blood (2019) 134 (Supplement_1): 400.

https://doi.org/10.1182/blood-2019-124017

Published: 2019

Journal Articles

Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients

Jorne Lionel Biccler, MSc, BSc, Ingrid Glimelius, MD PhD, Sandra Eloranta, Knut B. Smeland, Peter de Nully Brown, MD PhD, Lasse H. Jakobsen, Henrik Frederiksen, MD PhD, Mats Jerkeman, Alexander Fosså, MD PhD, Therese M.L. Andersson, PhD, Harald Holte, Jr., MD PhD, Martin Bøgsted, Professor, Tarec C. El-Galaly, Karin Ekstroem Smedby, MDPhD

Blood (2018) 132 (Supplement 1): 930.

https://doi.org/10.1182/blood-2018-99-111759

Published: 2018

Journal Articles

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Jorne Lionel Biccler, MSc, BSc, Kerry J Savage, BSc, MD MSc, Peter de Nully Brown, MD PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Christian Bjørn Poulsen, MD, Danny Stoltenberg, MD, Lasse H. Jakobsen, Martin Bøgsted, Professor, Diego Villa, MD, Tarec C. El-Galaly

Blood (2018) 132 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2018-99-114191

Published: 2018

Journal Articles

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, MD PhD, Eva Kimby

Blood (2017) 130 (Supplement 1): 2768.

https://doi.org/10.1182/blood.V130.Suppl_1.2768.2768

Published: 2017

Journal Articles

Lymphoma Patients Treated without Anthracyclines Have Negligible Risk of Cardiotoxicity: A Nationwide Cohort Study

Joachim Baech, Steen Moeller Hansen, Peter Enemark Lund, Christian Torp-Pedersen, Peter Soegaard, Peter de Nully Brown, MD PhD, Henrik Frederiksen, Judit Mészáros Jørgensen, Joern Starklint, Pär Josefsson, MD PhD, Christian Bjørn Poulsen, Hans Erik Johnsen, MD Professor, Tarec Christoffer El-Galaly, MD PhD

Blood (2017) 130 (Supplement 1): 2843.

https://doi.org/10.1182/blood.V130.Suppl_1.2843.2843

Published: 2017

Journal Articles

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Tove Wästerlid, MD PhD, Jorne Lionel Biccler, MSc, Peter de Nully Brown, MD PhD, Jacob Haaber Christensen, MD PhD, Gunilla Enblad, MD PhD, Judit Mészáros Jørgensen, Karin E Smedby, MD PhD, Tarec Christoffer El-Galaly, MD PhD, Mats Jerkeman, MD PhD

Blood (2017) 130 (Supplement 1): 1560.

https://doi.org/10.1182/blood.V130.Suppl_1.1560.1560

Published: 2017

Journal Articles

Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study

Mette Dahl Bendtsen, MSc, Lasse Hjort Jakobsen, MSc, Judit Mészáros Jørgensen, Hans Erik Johnsen, MD Professor, Pär Lars Josefsson, MD, Christian Bjørn Poulsen, Jørn Starklint, MD, Gabriela Felicia Stein, MD, Per Trøllund Pedersen, MD, Jacob Haaber Christensen, MD PhD, Martin Bøgsted, Professor, Peter de Nully Brown, MD PhD, Tarec Christoffer El-Galaly, MD PhD

Blood (2017) 130 (Supplement 1): 1561.

https://doi.org/10.1182/blood.V130.Suppl_1.1561.1561

Published: 2017

Journal Articles

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Adam Vilmar, PhD MD, Bente Arboe, Par Josefsson, MD PhD, Christian Poulsen, Jacob Haaber Christensen, Judit Jørgensen, MD PhD, Paw Jensen, Jørn Starklint, Per Troellund Pedersen, Michael Pedersen, Peter de Nully Brown, MD PhD

Blood (2016) 128 (22): 1781.

https://doi.org/10.1182/blood.V128.22.1781.1781

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Christian Winther Eskelund, Jakob W Hansen, Maj Karoline Westman, MSc, Catja Freiburghaus, PhD, Sara Ek, PhD, Lone B Pedersen, Mette K Andersen, Riikka Räty, Arne Kolstad, Mats Jerkeman, Peter de Nully Brown, MD PhD, Christian H Geisler, Kirsten Groenbaek

Blood (2016) 128 (22): 1095.

https://doi.org/10.1182/blood.V128.22.1095.1095

Published: 2016

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Social Outcomes after High Dose Chemotherapy with Autologous Stem Cell Transplant

Bente Arboe, Jette Soenderskov Goerloev, MD, Maja Halgren Olsen, Susanne Oksbjerg Dalton, Kristina Fruerlund Nielsen, Soeren Ramme Nielsen, Charlotte Madsen, MD, Rasmus Nielsen, Peter de Nully Brown, MD PhD

Blood (2016) 128 (22): 1193.

https://doi.org/10.1182/blood.V128.22.1193.1193

Published: 2016

Journal Articles

Quality of Life in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-14 Based Chemotherapy Is Only Affected Temporarily

Dorte Tholstrup, MD, Jesper Jurlander, MD, PhD, Palle Bekker Jeppesen, MD, PhD, DrMSci, Peter de Nully Brown, MD, PhD

Blood (2008) 112 (11): 2384.

https://doi.org/10.1182/blood.V112.11.2384.2384

Published: 2008

Journal Articles

Efficacy and Safety of CHOP-14 in Elderly Patients with Very Poor Risk Diffuse Large B-Cell Lymphoma.

Dorte Tholstrup, MD, Peter de Nully Brown, MD, PhD, Mads Hansen, MD, DrMSci, Jesper Jurlander, MD, PhD

Blood (2004) 104 (11): 3307.

https://doi.org/10.1182/blood.V104.11.3307.3307

Published: 2004

NARROW

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Lymphoma Patients Treated without Anthracyclines Have Negligible Risk of Cardiotoxicity: A Nationwide Cohort Study

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Social Outcomes after High Dose Chemotherapy with Autologous Stem Cell Transplant

Quality of Life in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-14 Based Chemotherapy Is Only Affected Temporarily

Efficacy and Safety of CHOP-14 in Elderly Patients with Very Poor Risk Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only